SlideShare a Scribd company logo
1 of 25
Download to read offline
Procalcitonin and MR-proAdrenomedullin as
diagnostic and prognostic biomarkers in ICU
lung transplanted patients


Andrea Senna
Clinical Research/Innovation in Pneumonia and Sepsis (CRIPS)
Vall d’Hebron Institut de Recerca (VHIR)




                                                               Compromís, expertesa i integració
Lung Transplantation


•   Lung transplantation is the only established therapeutic treatment
    which can extend life expectancy in patients with advanced
    end-stage pulmonary disease.

•   The survival rate of patients after 5 years rapidly decrease to 50%,
    an extremely low number.

•   The lung transplant has particular and distinctive characteristics that
    separate them from other solid organ transplantations.



                                                            (Ahmad S, Shlobin OA, 2011)

                                                                          FIS PI11/01122
ARF in Lung Transplant

•   Several complications have been described to be responsible of low
    survival rate after lung transplantation:
     – Acute Rejection
     – Infections

•   Both complications occur in the form of Acute Respiratory Failure
    (ARF), being difficult for clinicians to differentiate the cause at
    baseline

•   Both complications greatly differ in treatment options

•   So far, no reliable methods are available for anticipating the
    diagnosis of complications
                                                             (Christie JD, Edwards LE, 2011)

                                                                              FIS PI11/01122
Procalcitonin (PCT)
•   Precursor peptide from the hormone calcitonin

•   Has 2 differents type of metabolism depending on the presence of
    bacterial infection.

•   PCT is released in response to bacterial toxins and pro-inflammatory
    mediators

•   PCT is known as one of the most effective markers of bacterial
    sepsis

•   Only few studies has evaluated the usefulness of PCT in LT patients

                                                               (Bloos et al, 2011)

                                                                      FIS PI11/01122
MR pro-Adrenomedullin (proADM)

•   MR-proADM is a fragment of pro-ADM, the precursor of
    Adrenomedullin

•   Directly reflects levels of ADM

•   MR-proADM is a member of calcitonin peptides family

•   Widely expressed during severe infections

•   MR-proADM has several effects including immune modulation and
    vasodilatation

                                                           (Huang et al, 2009)

                                                                   FIS PI11/01122
Hypothesis

• We aim to assess Procalcitonin and pro-Adrenomedullin as
  biomarkers for lung transplant short-term complications during
  post-surgical ICU stay


 Objectives
 • to Test the capacity of PCT and proADM to differentiate between Acute Graft
 Rejection and Lung Infection

 • to Value the usefulness of PCT and pro-Adremedullin as a prognostic factor
 of mortality



                                                                         FIS PI11/01122
Material & Methods

•   Single center prospective observational study in the ICU Hospital Vall
    d'Hebron
•   100 Lung transplanted patients (36 already recluted)
•   Clinical and demographic characteristics of all patients are registered
•   Approved from the Ethical Committee


• Blood samples is collected at days 1,2,3 and 7 after ICU admission (post-
transplant)
• Upon Acute Respiratory Failure (ARF) detection, blood was collected for the
3 next consecutive days
• PCT y pro-ADM values were measured by BRAHMS Kryptor Technology
• Diagnose of the different complications was supported by clinical findings
according to the latest consensus definitions


                                                                              FIS PI11/01122
Results




          FIS PI11/01122
Transplant Indications
                                              N=36




                         Bronchiecstasis




                         Pulm. hypertension




                                                 FIS PI11/01122
Type of Transplant
                            N=36
         Left Unilateral;
             13, 36%




      Right Unilateral;
          5, 14%



                               FIS PI11/01122
Acute Respiratory Failure (ARF)
                                           N=36


                                  4, 44%




                                                  5, 56%




                                             FIS PI11/01122
Mortality
            N=36




              FIS PI11/01122
Flowchart

                               Lung Transplants
                                   N = 36




-PCT                NO - ARF                          ARF
-proADM              (n=27)                          (n=9)




          -PCT                          Infections           Rejection
          -proADM                         (n=5)               (n=4)




                                                                         FIS PI11/01122
PCT and MR-proADM




                    FIS PI11/01122
Procalcitonin (PCT) - ARF vs. NO ARF




                                       FIS PI11/01122
Procalcitonin (PCT) – Infection VS. Rejection




                                                FIS PI11/01122
Procalcitonin (PCT) – Infection VS. Rejection (IRA)




                                                FIS PI11/01122
Procalcitonin (PCT) - Mortality




                                  FIS PI11/01122
MR Pro-Adrenomedullin (pro-ADM)   – ARF VS. NO ARF




                                                     FIS PI11/01122
MR Pro-Adrenomedullin (pro-ADM) – Infection   VS. Rejection




                                                      FIS PI11/01122
MR Pro-Adrenomedullin (pro-ADM) – Infection   VS. Rejection




                                                      FIS PI11/01122
MR Pro-Adrenomedullin (pro-ADM) - Mortality




                                              FIS PI11/01122
Conclusions


•   The number of patients undergoing a complication is far too small
    for definitive conclusions

•   Preliminary data are encouraging towards the ability of PCT and
    proADM to diagnose the patients that suffer lung transplant
    complications

•   Data suggest proADM may have a prognostic value over mortality at
    first day of ICU admission




                                                                      FIS PI11/01122
Ongoing
1) Analyze and correlate changes in Exhaled Breath Condensate (EBC) and
   BroncoAlveolar Lavage (BAL) with difference in PCT and MR-proADM

2) Include in the analysis changes of CRP values in plasma

3) Analyze and quantify IL6, IL8, IL10 patterns with ELISA methods for specific
   inflammation response

4) Correlate clinical variable and respiratory pattern of the donors with the ARF
   after lung transplant

5) To evaluate correletion of microorganism with specific patterns of
   biomarkers in infections



                                                                             FIS PI11/01122
Aknowledgment

                Jordi Rello, MD, PhD

                Judit Sacanell, MD

                Laura Ruano, MSc

                Elsa Afonso, MSc

                Melissa Fernandez, MSc




                                         FIS PI11/01122

More Related Content

What's hot

current status of GP2B3A inhibitors in PCI
current status of GP2B3A inhibitors in PCIcurrent status of GP2B3A inhibitors in PCI
current status of GP2B3A inhibitors in PCIKunal Mahajan
 
Gp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotangGp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotangKiran Sotang
 
Sugammadex in the management of sinus
Sugammadex in the management of sinusSugammadex in the management of sinus
Sugammadex in the management of sinusCarlos D A Bersot
 
Renal Transplantation Dr. Jorge L. Posada
Renal Transplantation   Dr. Jorge L. PosadaRenal Transplantation   Dr. Jorge L. Posada
Renal Transplantation Dr. Jorge L. PosadaMedicineAndHealthCancer
 
Trauma induced coagulopathy
Trauma induced coagulopathyTrauma induced coagulopathy
Trauma induced coagulopathyAbdulgafoor MT
 
Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...
Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...
Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...degarden
 
Poster 33 biochimie
Poster 33 biochimiePoster 33 biochimie
Poster 33 biochimieJIB Congress
 
Early repolarisation syndrome
Early repolarisation syndromeEarly repolarisation syndrome
Early repolarisation syndromenmonty02
 
The Many Facets of Acquired Haemophilia
The Many Facets of Acquired HaemophiliaThe Many Facets of Acquired Haemophilia
The Many Facets of Acquired Haemophiliawai2k
 
heart sessions summary 11th banff conference on allograft pathology
heart sessions summary 11th banff conference on allograft pathologyheart sessions summary 11th banff conference on allograft pathology
heart sessions summary 11th banff conference on allograft pathologyKim Solez ,
 
Early reperfusion in myocardial infarction
Early reperfusion in myocardial infarctionEarly reperfusion in myocardial infarction
Early reperfusion in myocardial infarctioncardiositeindia
 
Early repolarisation syndrome (2)
Early repolarisation syndrome (2)Early repolarisation syndrome (2)
Early repolarisation syndrome (2)DR. VINIT KUMAR
 
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenuesLLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenuesEuropean School of Oncology
 

What's hot (20)

current status of GP2B3A inhibitors in PCI
current status of GP2B3A inhibitors in PCIcurrent status of GP2B3A inhibitors in PCI
current status of GP2B3A inhibitors in PCI
 
Gp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotangGp IIa IIIb inhibitor- kiran sotang
Gp IIa IIIb inhibitor- kiran sotang
 
Sugammadex in the management of sinus
Sugammadex in the management of sinusSugammadex in the management of sinus
Sugammadex in the management of sinus
 
Dental management in patients receiving anticoagulation or antiplatelet tre...
Dental management  in patients receiving anticoagulation or antiplatelet  tre...Dental management  in patients receiving anticoagulation or antiplatelet  tre...
Dental management in patients receiving anticoagulation or antiplatelet tre...
 
Ectopic Paroxysmal Atrial Tachycardia
Ectopic Paroxysmal Atrial Tachycardia  Ectopic Paroxysmal Atrial Tachycardia
Ectopic Paroxysmal Atrial Tachycardia
 
Interdepartment Wafarin
Interdepartment WafarinInterdepartment Wafarin
Interdepartment Wafarin
 
Renal Transplantation Dr. Jorge L. Posada
Renal Transplantation   Dr. Jorge L. PosadaRenal Transplantation   Dr. Jorge L. Posada
Renal Transplantation Dr. Jorge L. Posada
 
International Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & DiagnosisInternational Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & Diagnosis
 
Trauma induced coagulopathy
Trauma induced coagulopathyTrauma induced coagulopathy
Trauma induced coagulopathy
 
Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...
Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...
Interferon-ß Treatment Eliminates Cardiotropic Viruses and Improves Left Vent...
 
Poster 33 biochimie
Poster 33 biochimiePoster 33 biochimie
Poster 33 biochimie
 
Early repolarisation syndrome
Early repolarisation syndromeEarly repolarisation syndrome
Early repolarisation syndrome
 
The Many Facets of Acquired Haemophilia
The Many Facets of Acquired HaemophiliaThe Many Facets of Acquired Haemophilia
The Many Facets of Acquired Haemophilia
 
Early repolarization
Early repolarizationEarly repolarization
Early repolarization
 
heart sessions summary 11th banff conference on allograft pathology
heart sessions summary 11th banff conference on allograft pathologyheart sessions summary 11th banff conference on allograft pathology
heart sessions summary 11th banff conference on allograft pathology
 
Early reperfusion in myocardial infarction
Early reperfusion in myocardial infarctionEarly reperfusion in myocardial infarction
Early reperfusion in myocardial infarction
 
Early repolarisation syndrome (2)
Early repolarisation syndrome (2)Early repolarisation syndrome (2)
Early repolarisation syndrome (2)
 
SOT Poster Final 2016
SOT Poster Final 2016SOT Poster Final 2016
SOT Poster Final 2016
 
Atrial tachycardia_lecture
Atrial tachycardia_lectureAtrial tachycardia_lecture
Atrial tachycardia_lecture
 
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenuesLLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
 

Viewers also liked

Significance of serum procalcitonin in sepsis
Significance   of    serum procalcitonin    in  sepsisSignificance   of    serum procalcitonin    in  sepsis
Significance of serum procalcitonin in sepsisLakshya K Solanki
 
Serum Procalcitonin as a marker of infection in chronic kidney disease patien...
Serum Procalcitonin as a marker of infection in chronic kidney disease patien...Serum Procalcitonin as a marker of infection in chronic kidney disease patien...
Serum Procalcitonin as a marker of infection in chronic kidney disease patien...iosrjce
 
Role of Biomarkers Sepsis
Role of Biomarkers SepsisRole of Biomarkers Sepsis
Role of Biomarkers SepsisNireshan Naidoo
 
The role of human factors in the fight against sepsis
The role of human factors in the fight against sepsisThe role of human factors in the fight against sepsis
The role of human factors in the fight against sepsisGiulio Toccafondi
 
The third international consensus definitions for sepsis and septic shock (se...
The third international consensus definitions for sepsis and septic shock (se...The third international consensus definitions for sepsis and septic shock (se...
The third international consensus definitions for sepsis and septic shock (se...Daniela Botero Echeverri
 
Biomarkers in sepsis
Biomarkers in sepsisBiomarkers in sepsis
Biomarkers in sepsisNIICS
 
ACTEP2014: Sepsis marker in clinical use
ACTEP2014: Sepsis marker in clinical useACTEP2014: Sepsis marker in clinical use
ACTEP2014: Sepsis marker in clinical usetaem
 
Neonatal Sepsis And Recent Challenges
Neonatal Sepsis And Recent ChallengesNeonatal Sepsis And Recent Challenges
Neonatal Sepsis And Recent ChallengesDang Thanh Tuan
 
Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...
Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...
Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...Luanvanyhoc.com-Zalo 0927.007.596
 
Biomarkers in Emergency Medicine: Katrin Hruska
Biomarkers in Emergency Medicine: Katrin HruskaBiomarkers in Emergency Medicine: Katrin Hruska
Biomarkers in Emergency Medicine: Katrin HruskaSMACC Conference
 
Các dung dịch thường dùng trong hscc yhocthuchanh2015
Các dung dịch thường dùng trong hscc yhocthuchanh2015Các dung dịch thường dùng trong hscc yhocthuchanh2015
Các dung dịch thường dùng trong hscc yhocthuchanh2015Tuấn Anh Bùi
 
Định nghĩa mới về Sepsis 3.0
Định nghĩa mới về Sepsis 3.0Định nghĩa mới về Sepsis 3.0
Định nghĩa mới về Sepsis 3.0Thanh Liem Vo
 
Nhiễm trùng toàn thân và sốc nhiễm trùng
Nhiễm trùng toàn thân và sốc nhiễm trùngNhiễm trùng toàn thân và sốc nhiễm trùng
Nhiễm trùng toàn thân và sốc nhiễm trùngNguyen Rain
 
ICU Scoring Systems
ICU Scoring SystemsICU Scoring Systems
ICU Scoring SystemsIman Galal
 

Viewers also liked (20)

Significance of serum procalcitonin in sepsis
Significance   of    serum procalcitonin    in  sepsisSignificance   of    serum procalcitonin    in  sepsis
Significance of serum procalcitonin in sepsis
 
Diagnostic_Dossier_December_2014_HE
Diagnostic_Dossier_December_2014_HEDiagnostic_Dossier_December_2014_HE
Diagnostic_Dossier_December_2014_HE
 
Procalcitonin
ProcalcitoninProcalcitonin
Procalcitonin
 
Serum Procalcitonin as a marker of infection in chronic kidney disease patien...
Serum Procalcitonin as a marker of infection in chronic kidney disease patien...Serum Procalcitonin as a marker of infection in chronic kidney disease patien...
Serum Procalcitonin as a marker of infection in chronic kidney disease patien...
 
Role of Biomarkers Sepsis
Role of Biomarkers SepsisRole of Biomarkers Sepsis
Role of Biomarkers Sepsis
 
194504028 cc8872
194504028 cc8872194504028 cc8872
194504028 cc8872
 
The role of human factors in the fight against sepsis
The role of human factors in the fight against sepsisThe role of human factors in the fight against sepsis
The role of human factors in the fight against sepsis
 
Procalcitonin
ProcalcitoninProcalcitonin
Procalcitonin
 
The third international consensus definitions for sepsis and septic shock (se...
The third international consensus definitions for sepsis and septic shock (se...The third international consensus definitions for sepsis and septic shock (se...
The third international consensus definitions for sepsis and septic shock (se...
 
Biomarkers in sepsis
Biomarkers in sepsisBiomarkers in sepsis
Biomarkers in sepsis
 
ACTEP2014: Sepsis marker in clinical use
ACTEP2014: Sepsis marker in clinical useACTEP2014: Sepsis marker in clinical use
ACTEP2014: Sepsis marker in clinical use
 
Neonatal Sepsis And Recent Challenges
Neonatal Sepsis And Recent ChallengesNeonatal Sepsis And Recent Challenges
Neonatal Sepsis And Recent Challenges
 
Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...
Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...
Đặc điểm lâm sàng, cận lâm sàng và điều trị viêm phổi cộng đồng ở bệnh nhân n...
 
Biomarkers in Emergency Medicine: Katrin Hruska
Biomarkers in Emergency Medicine: Katrin HruskaBiomarkers in Emergency Medicine: Katrin Hruska
Biomarkers in Emergency Medicine: Katrin Hruska
 
Các dung dịch thường dùng trong hscc yhocthuchanh2015
Các dung dịch thường dùng trong hscc yhocthuchanh2015Các dung dịch thường dùng trong hscc yhocthuchanh2015
Các dung dịch thường dùng trong hscc yhocthuchanh2015
 
Sepsis markers
Sepsis markersSepsis markers
Sepsis markers
 
Định nghĩa mới về Sepsis 3.0
Định nghĩa mới về Sepsis 3.0Định nghĩa mới về Sepsis 3.0
Định nghĩa mới về Sepsis 3.0
 
Nhiễm trùng toàn thân và sốc nhiễm trùng
Nhiễm trùng toàn thân và sốc nhiễm trùngNhiễm trùng toàn thân và sốc nhiễm trùng
Nhiễm trùng toàn thân và sốc nhiễm trùng
 
Lung transplantation.ppt
Lung transplantation.pptLung transplantation.ppt
Lung transplantation.ppt
 
ICU Scoring Systems
ICU Scoring SystemsICU Scoring Systems
ICU Scoring Systems
 

Similar to Procalcitonin and MR-proAdrenomedullin as diagnostic and prognostic biomarkers in ICU lung transplanted patients

Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...
Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...
Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...Federal University of Bahia
 
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosisarshadsmc
 
Idiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptx
Idiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptxIdiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptx
Idiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptxKefelegnNathan1
 
Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...
Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...
Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...DrTapasTripathi
 
Advances In Critical Care: 25 Years Prespective
Advances In Critical Care: 25 Years PrespectiveAdvances In Critical Care: 25 Years Prespective
Advances In Critical Care: 25 Years PrespectiveDr.Mahmoud Abbas
 
Prognostic Role Of Aa Do2 In Acute Pulmonary Embolism
Prognostic Role Of Aa Do2 In Acute Pulmonary EmbolismPrognostic Role Of Aa Do2 In Acute Pulmonary Embolism
Prognostic Role Of Aa Do2 In Acute Pulmonary EmbolismDang Thanh Tuan
 
Idiopathic interstitial pneumonias
Idiopathic interstitial pneumoniasIdiopathic interstitial pneumonias
Idiopathic interstitial pneumoniasArvind Ghongane
 
idiopathicinterstitialpneumonias-180108181014 (1).pdf
idiopathicinterstitialpneumonias-180108181014 (1).pdfidiopathicinterstitialpneumonias-180108181014 (1).pdf
idiopathicinterstitialpneumonias-180108181014 (1).pdfDrYaqoobBahar
 
04. Best of ILD 2022.pptx
04. Best of ILD 2022.pptx04. Best of ILD 2022.pptx
04. Best of ILD 2022.pptxvipulranjan16
 
2012 cts guidline_alpha-1
2012 cts guidline_alpha-12012 cts guidline_alpha-1
2012 cts guidline_alpha-1Ihsaan Peer
 
Gastroenterologist-directed propofol.
Gastroenterologist-directed propofol.Gastroenterologist-directed propofol.
Gastroenterologist-directed propofol.Shaikhani.
 
Progressive Pulmonary Fibrosis definition & management
Progressive Pulmonary Fibrosis definition & managementProgressive Pulmonary Fibrosis definition & management
Progressive Pulmonary Fibrosis definition & managementSubhajit Ghosh
 
Mesa 1.4.Dr Jose Luis López Campos
Mesa 1.4.Dr Jose Luis López CamposMesa 1.4.Dr Jose Luis López Campos
Mesa 1.4.Dr Jose Luis López CamposQuim Fuster
 
Mesa 1.4. Dr Jose Luis López Campos
Mesa 1.4. Dr Jose Luis López CamposMesa 1.4. Dr Jose Luis López Campos
Mesa 1.4. Dr Jose Luis López CamposFERRER EPOCSITE PRO
 

Similar to Procalcitonin and MR-proAdrenomedullin as diagnostic and prognostic biomarkers in ICU lung transplanted patients (20)

Pphn 2008
Pphn 2008Pphn 2008
Pphn 2008
 
The Role of the Eosinophil in COPD: Implications for Precision Care and Novel...
The Role of the Eosinophil in COPD: Implications for Precision Care and Novel...The Role of the Eosinophil in COPD: Implications for Precision Care and Novel...
The Role of the Eosinophil in COPD: Implications for Precision Care and Novel...
 
RA-ILD
RA-ILDRA-ILD
RA-ILD
 
12 FFR Sayan S aimradial2016 - iFr trials
12 FFR Sayan S aimradial2016  - iFr trials12 FFR Sayan S aimradial2016  - iFr trials
12 FFR Sayan S aimradial2016 - iFr trials
 
Intraocular Pressure Changes Following Laryngoscopy and Tracheal Inubation wi...
Intraocular Pressure Changes Following Laryngoscopy and Tracheal Inubation wi...Intraocular Pressure Changes Following Laryngoscopy and Tracheal Inubation wi...
Intraocular Pressure Changes Following Laryngoscopy and Tracheal Inubation wi...
 
Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...
Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...
Beneficial Effect of Plasmapheresis and IVIG on Renal Allograft Survival of P...
 
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis
 
Idiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptx
Idiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptxIdiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptx
Idiopathic Interstitial Pneumonia With Autoimmune Features(IPAF).pptx
 
Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...
Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...
Predictors of Outcome in Acute Respiratory Distress Syndrome with Acute febri...
 
AFFIRM-AHF: diseño y resultados
AFFIRM-AHF: diseño y resultadosAFFIRM-AHF: diseño y resultados
AFFIRM-AHF: diseño y resultados
 
Advances In Critical Care: 25 Years Prespective
Advances In Critical Care: 25 Years PrespectiveAdvances In Critical Care: 25 Years Prespective
Advances In Critical Care: 25 Years Prespective
 
Prognostic Role Of Aa Do2 In Acute Pulmonary Embolism
Prognostic Role Of Aa Do2 In Acute Pulmonary EmbolismPrognostic Role Of Aa Do2 In Acute Pulmonary Embolism
Prognostic Role Of Aa Do2 In Acute Pulmonary Embolism
 
Idiopathic interstitial pneumonias
Idiopathic interstitial pneumoniasIdiopathic interstitial pneumonias
Idiopathic interstitial pneumonias
 
idiopathicinterstitialpneumonias-180108181014 (1).pdf
idiopathicinterstitialpneumonias-180108181014 (1).pdfidiopathicinterstitialpneumonias-180108181014 (1).pdf
idiopathicinterstitialpneumonias-180108181014 (1).pdf
 
04. Best of ILD 2022.pptx
04. Best of ILD 2022.pptx04. Best of ILD 2022.pptx
04. Best of ILD 2022.pptx
 
2012 cts guidline_alpha-1
2012 cts guidline_alpha-12012 cts guidline_alpha-1
2012 cts guidline_alpha-1
 
Gastroenterologist-directed propofol.
Gastroenterologist-directed propofol.Gastroenterologist-directed propofol.
Gastroenterologist-directed propofol.
 
Progressive Pulmonary Fibrosis definition & management
Progressive Pulmonary Fibrosis definition & managementProgressive Pulmonary Fibrosis definition & management
Progressive Pulmonary Fibrosis definition & management
 
Mesa 1.4.Dr Jose Luis López Campos
Mesa 1.4.Dr Jose Luis López CamposMesa 1.4.Dr Jose Luis López Campos
Mesa 1.4.Dr Jose Luis López Campos
 
Mesa 1.4. Dr Jose Luis López Campos
Mesa 1.4. Dr Jose Luis López CamposMesa 1.4. Dr Jose Luis López Campos
Mesa 1.4. Dr Jose Luis López Campos
 

More from Vall d'Hebron Institute of Research (VHIR)

"Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu...
"Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu..."Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu...
"Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu...Vall d'Hebron Institute of Research (VHIR)
 
"Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ...
"Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ..."Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ...
"Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ...Vall d'Hebron Institute of Research (VHIR)
 
Using and combining the different tools for predicting the pathogenicity of s...
Using and combining the different tools for predicting the pathogenicity of s...Using and combining the different tools for predicting the pathogenicity of s...
Using and combining the different tools for predicting the pathogenicity of s...Vall d'Hebron Institute of Research (VHIR)
 
Interpretation of sequence variants in the biomedical environment: what shoul...
Interpretation of sequence variants in the biomedical environment: what shoul...Interpretation of sequence variants in the biomedical environment: what shoul...
Interpretation of sequence variants in the biomedical environment: what shoul...Vall d'Hebron Institute of Research (VHIR)
 
Variant calling and how to prioritize somatic mutations and inheritated varia...
Variant calling and how to prioritize somatic mutations and inheritated varia...Variant calling and how to prioritize somatic mutations and inheritated varia...
Variant calling and how to prioritize somatic mutations and inheritated varia...Vall d'Hebron Institute of Research (VHIR)
 
"Rare diseases as platform to develop novel therapeutic strategies: the examp...
"Rare diseases as platform to develop novel therapeutic strategies: the examp..."Rare diseases as platform to develop novel therapeutic strategies: the examp...
"Rare diseases as platform to develop novel therapeutic strategies: the examp...Vall d'Hebron Institute of Research (VHIR)
 
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ..."Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...Vall d'Hebron Institute of Research (VHIR)
 
Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...
Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...
Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...Vall d'Hebron Institute of Research (VHIR)
 
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To..."Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...Vall d'Hebron Institute of Research (VHIR)
 
Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...
Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...
Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...Vall d'Hebron Institute of Research (VHIR)
 
Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...
Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...
Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...Vall d'Hebron Institute of Research (VHIR)
 
Acute kidney injury in critically ill patients in the new millenium: definiti...
Acute kidney injury in critically ill patients in the new millenium: definiti...Acute kidney injury in critically ill patients in the new millenium: definiti...
Acute kidney injury in critically ill patients in the new millenium: definiti...Vall d'Hebron Institute of Research (VHIR)
 

More from Vall d'Hebron Institute of Research (VHIR) (20)

Human Cell Line Authentication. Why is it so important?
Human Cell Line Authentication. Why is it so important?Human Cell Line Authentication. Why is it so important?
Human Cell Line Authentication. Why is it so important?
 
"Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu...
"Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu..."Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu...
"Neurobiología del parto y vínculo materno-filial: eventos no fisiológicos qu...
 
"Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ...
"Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ..."Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ...
"Nuevas perspectivas médicas para luchar contra las enfermedades asociadas a ...
 
Using and combining the different tools for predicting the pathogenicity of s...
Using and combining the different tools for predicting the pathogenicity of s...Using and combining the different tools for predicting the pathogenicity of s...
Using and combining the different tools for predicting the pathogenicity of s...
 
Interpretation of sequence variants in the biomedical environment: what shoul...
Interpretation of sequence variants in the biomedical environment: what shoul...Interpretation of sequence variants in the biomedical environment: what shoul...
Interpretation of sequence variants in the biomedical environment: what shoul...
 
Variant calling and how to prioritize somatic mutations and inheritated varia...
Variant calling and how to prioritize somatic mutations and inheritated varia...Variant calling and how to prioritize somatic mutations and inheritated varia...
Variant calling and how to prioritize somatic mutations and inheritated varia...
 
Data analysis pipelines for NGS applications
Data analysis pipelines for NGS applicationsData analysis pipelines for NGS applications
Data analysis pipelines for NGS applications
 
NGS and the molecular basis of disease: a practical view
NGS and the molecular basis of disease: a practical viewNGS and the molecular basis of disease: a practical view
NGS and the molecular basis of disease: a practical view
 
Prof. Adolfo García Sastre: Influenza epidemics and pandemics
Prof. Adolfo García Sastre: Influenza epidemics and pandemicsProf. Adolfo García Sastre: Influenza epidemics and pandemics
Prof. Adolfo García Sastre: Influenza epidemics and pandemics
 
"Rare diseases as platform to develop novel therapeutic strategies: the examp...
"Rare diseases as platform to develop novel therapeutic strategies: the examp..."Rare diseases as platform to develop novel therapeutic strategies: the examp...
"Rare diseases as platform to develop novel therapeutic strategies: the examp...
 
Richard horton, barcelona 2014
Richard horton, barcelona 2014Richard horton, barcelona 2014
Richard horton, barcelona 2014
 
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ..."Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
 
Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...
Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...
Dr. Esteban Domingo: Respuesta del virus de la hepatitis C a inhibidores. Inf...
 
"Biomarkers in sepsis and septic shock" by Prof. Jérôme Pugin
"Biomarkers in sepsis and septic shock" by Prof. Jérôme Pugin"Biomarkers in sepsis and septic shock" by Prof. Jérôme Pugin
"Biomarkers in sepsis and septic shock" by Prof. Jérôme Pugin
 
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To..."Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
 
Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...
Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...
Sr. Juan Carrión: 'Unidos nuestros derechos avanzan: análisis de las 14 propu...
 
Dr. Tobias Welte: Lessons learned from the CAPNETZ study
Dr. Tobias Welte: Lessons learned from the CAPNETZ studyDr. Tobias Welte: Lessons learned from the CAPNETZ study
Dr. Tobias Welte: Lessons learned from the CAPNETZ study
 
Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...
Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...
Dr. Jordi Llinares: Research, regulations and rare deseases. Is there a meeti...
 
IRDiRC: State of the Art. By Paul Lasko, PhD
IRDiRC: State of the Art. By Paul Lasko, PhDIRDiRC: State of the Art. By Paul Lasko, PhD
IRDiRC: State of the Art. By Paul Lasko, PhD
 
Acute kidney injury in critically ill patients in the new millenium: definiti...
Acute kidney injury in critically ill patients in the new millenium: definiti...Acute kidney injury in critically ill patients in the new millenium: definiti...
Acute kidney injury in critically ill patients in the new millenium: definiti...
 

Procalcitonin and MR-proAdrenomedullin as diagnostic and prognostic biomarkers in ICU lung transplanted patients

  • 1. Procalcitonin and MR-proAdrenomedullin as diagnostic and prognostic biomarkers in ICU lung transplanted patients Andrea Senna Clinical Research/Innovation in Pneumonia and Sepsis (CRIPS) Vall d’Hebron Institut de Recerca (VHIR) Compromís, expertesa i integració
  • 2. Lung Transplantation • Lung transplantation is the only established therapeutic treatment which can extend life expectancy in patients with advanced end-stage pulmonary disease. • The survival rate of patients after 5 years rapidly decrease to 50%, an extremely low number. • The lung transplant has particular and distinctive characteristics that separate them from other solid organ transplantations. (Ahmad S, Shlobin OA, 2011) FIS PI11/01122
  • 3. ARF in Lung Transplant • Several complications have been described to be responsible of low survival rate after lung transplantation: – Acute Rejection – Infections • Both complications occur in the form of Acute Respiratory Failure (ARF), being difficult for clinicians to differentiate the cause at baseline • Both complications greatly differ in treatment options • So far, no reliable methods are available for anticipating the diagnosis of complications (Christie JD, Edwards LE, 2011) FIS PI11/01122
  • 4. Procalcitonin (PCT) • Precursor peptide from the hormone calcitonin • Has 2 differents type of metabolism depending on the presence of bacterial infection. • PCT is released in response to bacterial toxins and pro-inflammatory mediators • PCT is known as one of the most effective markers of bacterial sepsis • Only few studies has evaluated the usefulness of PCT in LT patients (Bloos et al, 2011) FIS PI11/01122
  • 5. MR pro-Adrenomedullin (proADM) • MR-proADM is a fragment of pro-ADM, the precursor of Adrenomedullin • Directly reflects levels of ADM • MR-proADM is a member of calcitonin peptides family • Widely expressed during severe infections • MR-proADM has several effects including immune modulation and vasodilatation (Huang et al, 2009) FIS PI11/01122
  • 6. Hypothesis • We aim to assess Procalcitonin and pro-Adrenomedullin as biomarkers for lung transplant short-term complications during post-surgical ICU stay Objectives • to Test the capacity of PCT and proADM to differentiate between Acute Graft Rejection and Lung Infection • to Value the usefulness of PCT and pro-Adremedullin as a prognostic factor of mortality FIS PI11/01122
  • 7. Material & Methods • Single center prospective observational study in the ICU Hospital Vall d'Hebron • 100 Lung transplanted patients (36 already recluted) • Clinical and demographic characteristics of all patients are registered • Approved from the Ethical Committee • Blood samples is collected at days 1,2,3 and 7 after ICU admission (post- transplant) • Upon Acute Respiratory Failure (ARF) detection, blood was collected for the 3 next consecutive days • PCT y pro-ADM values were measured by BRAHMS Kryptor Technology • Diagnose of the different complications was supported by clinical findings according to the latest consensus definitions FIS PI11/01122
  • 8. Results FIS PI11/01122
  • 9. Transplant Indications N=36 Bronchiecstasis Pulm. hypertension FIS PI11/01122
  • 10. Type of Transplant N=36 Left Unilateral; 13, 36% Right Unilateral; 5, 14% FIS PI11/01122
  • 11. Acute Respiratory Failure (ARF) N=36 4, 44% 5, 56% FIS PI11/01122
  • 12. Mortality N=36 FIS PI11/01122
  • 13. Flowchart Lung Transplants N = 36 -PCT NO - ARF ARF -proADM (n=27) (n=9) -PCT Infections Rejection -proADM (n=5) (n=4) FIS PI11/01122
  • 14. PCT and MR-proADM FIS PI11/01122
  • 15. Procalcitonin (PCT) - ARF vs. NO ARF FIS PI11/01122
  • 16. Procalcitonin (PCT) – Infection VS. Rejection FIS PI11/01122
  • 17. Procalcitonin (PCT) – Infection VS. Rejection (IRA) FIS PI11/01122
  • 18. Procalcitonin (PCT) - Mortality FIS PI11/01122
  • 19. MR Pro-Adrenomedullin (pro-ADM) – ARF VS. NO ARF FIS PI11/01122
  • 20. MR Pro-Adrenomedullin (pro-ADM) – Infection VS. Rejection FIS PI11/01122
  • 21. MR Pro-Adrenomedullin (pro-ADM) – Infection VS. Rejection FIS PI11/01122
  • 22. MR Pro-Adrenomedullin (pro-ADM) - Mortality FIS PI11/01122
  • 23. Conclusions • The number of patients undergoing a complication is far too small for definitive conclusions • Preliminary data are encouraging towards the ability of PCT and proADM to diagnose the patients that suffer lung transplant complications • Data suggest proADM may have a prognostic value over mortality at first day of ICU admission FIS PI11/01122
  • 24. Ongoing 1) Analyze and correlate changes in Exhaled Breath Condensate (EBC) and BroncoAlveolar Lavage (BAL) with difference in PCT and MR-proADM 2) Include in the analysis changes of CRP values in plasma 3) Analyze and quantify IL6, IL8, IL10 patterns with ELISA methods for specific inflammation response 4) Correlate clinical variable and respiratory pattern of the donors with the ARF after lung transplant 5) To evaluate correletion of microorganism with specific patterns of biomarkers in infections FIS PI11/01122
  • 25. Aknowledgment Jordi Rello, MD, PhD Judit Sacanell, MD Laura Ruano, MSc Elsa Afonso, MSc Melissa Fernandez, MSc FIS PI11/01122